

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.



ISSN: 0015-5659

e-ISSN: 1644-3284

Anatomy of the lymphatics in normal stomach and gastric carcinomas

Authors: Dimosthenis Chrysikos, Panagiotis Kanavaros, Alexandra Barbouti, Ameer Shehade, Dimitrios Liatsos, Alexandros Samolis, Th Theodore Troupis

DOI: 10.5603/fm.101667

Article type: Review article

Submitted: 2024-07-20

Accepted: 2024-08-20

Published online: 2024-09-16

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.

Articles in "Folia Morphologica" are listed in PubMed.

REVIEW ARTICLE

DOI: 10.5603/fm.101667

Anatomy of the lymphatics in normal stomach and gastric carcinomas

Dimosthenis Chrysikos^{1,*}, Panagiotis Kanavaros^{1,2,*}, Alexandra Barbouti², Ameer Shehade¹,
Dimitrios Liatsos¹, Alexandros Samolis,¹ Thoedore Troupis¹

¹Department of Anatomy, Faculty of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Greece

²Department of Anatomy-Histology-Embryology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

***These authors had equal contribution to this work.**

Address for correspondence: Dimosthenis Chrysikos, Department of Anatomy, Faculty of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Greece; Tel. +302107462379, e-mail: dichrysik@med.uoa.gr

ABSTRACT

The lymphatic system is composed of lymphoid organs/tissues and a complex network of lymphatic vessels that transport interstitial fluid, antigens, lipids, immune cells, and other materials in the body. There is growing evidence that lymphatic vasculature is associated with many pathological conditions such as lymphedema and cancer progression and metastasis. Thus, improved understanding of the anatomical features, the molecular profile and the function of the lymphatic vasculature may provide innovative approaches for disease prevention and treatment. This article aims to present a comprehensive review of the gastric lymphatic anatomy and its importance in the pathology, treatment and prognosis of gastric carcinomas.

Keywords: lymphatics, stomach, gastric cancer, surgical treatment, lymphadenectomy, skip metastasis

INTRODUCTION

The human lymphatic system is composed of lymphoid organs/tissues (thymus, spleen, lymph nodes, mucosa-associated lymphoid tissue) and a complex network of lymphatic vessels [1–8]. The lymphatic vasculature transports the lymph, a mix of interstitial fluid, immune cells,

lipids, antigens and other components and is implicated in the homeostasis of fluid balance, the immunosurveillance and the absorption of nutrients, especially lipids [1–3].

Recent advances in imaging and the discovery of novel cell biomarkers and single-cell biotechnologies improved the understanding of the anatomy of the lymphatic vasculature and the molecular profile of the lymphatic endothelial cells [1–3]. Notably, there is growing evidence that lymphatic vasculature is associated with a great array of pathological conditions including lymphedema (primary and secondary), inflammatory bowel disease such as Crohn disease, cardiovascular disease (atherosclerosis, myocardial infarction), eye disease such as glaucoma, neurological disorders such as Alzheimer disease, metabolism/obesity, and cancer progression and metastasis [1–3].

The lymphatic system provides an important route for the spread of malignancies; thus, the identification of lymphatic vascular pathways and lymphonodal stations of carcinoma spread is important for staging, choice of treatment, and the prediction of the prognosis of patients with malignant diseases [9–14]. For example, in the abdomen, the vascular pathways of lymphatic drainage accompany the blood vessels which supply or drain the abdominal organs, and are localized within the peritoneal ligaments, mesocolon or mesentery [9–12]. Malignant cells from the abdominal tumors such as gastric and colorectal carcinomas enter lymphatic vascular structures and travel to the lymph nodes (LN) along the lymphatic drainage pathways [9–14]. This article aims to review the gastric lymphatic anatomy [9–14] and its importance in the pathology, treatment and prognosis of gastric carcinomas [11–70].

BASIC ANATOMY OF THE LYMPHATICS

Before addressing the analysis of the lymphatic vasculature in normal stomach and gastric carcinomas, the general embryology, histology and macroscopic anatomy of the lymphatic vascular system is summarized [1–8].

Embryology

The basic concepts of the descriptive and molecular Embryology of the human lymphatic system were reported in previous reviews [3–7]. The increasing understanding of the molecular mechanisms that dictate the formation of the human lymphatic system in the early developmental stages are useful for gaining further insight in various physiological and pathological processes [6, 7]. The development of the human lymphatic system begins at the end of the sixth gestational week [4, 5]. Lymphatic vessels are lined with lymphatic

endothelial cells (LEC) which is an endothelial cell lineage characterized by specific transcriptional and metabolic program [6, 7]. LEC express the transcription factor prospero-related homeobox 1 (PROX1), which is involved in the establishment and maintenance of the lymphatic endothelial transcription program as well as the receptor tyrosine kinase vascular endothelial growth factor (VEGF) receptor-3 (VEGFR-3) [6, 7]. VEGFR-3 and its ligand, VEGF-C are a crucial growth factor pathway involved in normal and pathological lymphangiogenesis [6, 7]. During mammalian embryonic development, major population of LEC are derived from transdifferentiation of venous progenitors and give rise to dermal, cardiopulmonary, and hepatic lymphatic vessels [6, 7]. In addition to the venous-derived LEC, progenitors of non-venous origin contribute to the development of the lymphatic vasculature [6, 7]. The heterogeneous origin of LEC and the organ- and tissue-specific microenvironments contribute to the development of the organ- and tissue-specific characteristics and functions of LEC that are observed in the adult [6, 7].

Histology

The microscopic characteristics of the lymphatic vasculature were reported in previous reviews [7, 8]. Briefly, the lymphatic vessels are divided into three subtypes: initial lymphatics (capillary), pre-collectors and collecting lymphatics [8]. The initial lymphatics are blind-ended, non-contracting vessels with increased permeability which are composed of a single layer of LEC surrounded by a thin discontinuous basement membrane [7, 8]. The LEC of the collecting lymphatics are connected by continuous cell-cell junctions and are surrounded by a prominent basement membrane and contractile smooth muscle cells [7, 8]. Thus, collecting lymphatics are contractile and display reduced permeability. The accurate histological identification of lymphatic vessels requires the use of immunohistochemistry. Indeed, Adamczyk L.A. et al., 2016, reported had the most important specific immunohistochemical markers for lymphatic endothelium are podoplanin (D2-40), Prox-1, and lymphatic receptor for the extracellular matrix mucopolysaccharide hyaluronan (LYVE-1) [8]. They recommended the use of a panel consisting of one pan endothelial marker (p.e CD31) and two specific lymphatic endothelium markers for accurate identification of lymphatic vessels in normal tissues and the detection of lymphangiogenesis and lymphatic vessel invasion in cancer histopathology [8].

Macroscopic anatomy

The macroscopic anatomy of the lymphatic vasculature is variable and was described in previous reviews [4, 5]. Briefly, 3 major lymphatic vasculature structures can be identified, the right lymphatic duct, the cisterna chyli and the thoracic duct.

Firstly, the formation of the right lymphatic duct, which is approximately 1–2 cm in length, is a result of the merge of 3 other lesser lymphatic trunks, the right jugular, the right subclavian and the right bronchomediastinal. Its contents empty in the point of junction between the right subclavian and right internal jugular vein and originate from the right upper quadrant of the body, including the right arm, right side of the head and neck, right thorax, lung and diaphragm and part of the heart and right lobe of the liver [4, 5].

Secondly, the cisterna chyli resembles a dilated sac measuring about 5 cm in length and results from the junction of the right and left lumbar lymphatic trunks and the intestinal trunk, but significant anatomical variations have been noted regarding its formation [4, 5]. Regarding these variations, it is absent in 40–60% of the population and in those cases, the lumbar and intestinal lymphatics communicate directly with the thoracic duct. It is located on the level of L2 vertebra, but there are also variations ranging from T12-L2 level, between the aorta and the inferior vena cava [4, 5]. The lymph that it amasses originates from the abdominal wall area below the omphalic level, the pelvis, the kidneys and adrenal glands and part of the gastrointestinal tract being perfused by the celiac trunk and the superior mesenteric vessels [4, 5].

Lastly, the thoracic duct which is a continuation of the cisterna chyli measures around 45 cm in length and 2–5 cm in diameter [4, 5]. The thoracic duct is responsible for returning to the venous blood circulation 80–90% of the body's lymph, from every region except those that are irrigated from the right lymphatic duct [4, 5]. It starts at the level of the T12 vertebra and ascends through the aortic hiatus at T10 level, with the aorta to its left and the azygos vein to its right. During its ascent the duct is located anteriorly to the thoracic vertebrae and posteriorly to the esophagus, diaphragm and pericardium. During its course at the T7 level the duct crosses the midline of the spine obliquely until the level of T5. After that, being situated at the base of the neck and passing posterior to the common carotid artery, internal jugular vein, vagus nerve, left phrenic nerve and anterior to the vertebral artery and vein and the sympathetic trunk, it continues its course until C7, where it empties its content in the junction between the left internal jugular and subclavian veins. The thoracic duct can be divided into 3 parts, the abdominal, the thoracic and the cervical part. It should be noticed that the anatomy of the thoracic duct is subject to major variability, whether that concerns the number of ducts,

the connections of the duct with other minor veins or the way the duct empties in the junction of the major veins [4, 5].

LYMPHATICS IN NORMAL STOMACH

For the better understanding of the gastric lymphatic anatomy, the Japanese Classification of Gastric Carcinoma subdivides the stomach into 3 regions, the upper, the middle and the lower one, each with a different lymph drainage, and the Japanese Gastric Cancer Association classifies regional gastric LN into 33 separate stations [64].

These stations include both perigastric LN, situated along the vessels that feed the stomach, and LN along major vessels and adjacent to the pancreas, the diaphragm and esophageal hiatus [64].

The gastric lymphatic flow and the LN stations were presented in previous studies [10–14]. Briefly, the lymphatic flow of the stomach spreads from the perigastric nodes, *via* the suprapancreatic nodes and nodes around the celiac artery, to the para-aortic nodes, following which it enters the systemic circulation.

Considering the lymphatic flow with respect to the anatomical division of the stomach, the upper third of the stomach has lymphatics that follow the course the left gastric artery, the posterior gastric artery, the splenic artery and left inferior phrenic artery, but lacks lymphatic connection with the retropancreatic nodes which are situated along the posterior surface of the pancreas and with nodes around the superior mesenteric vessels (stations 13 and 14, respectively). The lymphatics of the lower third of the stomach run along the common hepatic and superior mesenteric arteries and ultimately drain into nodal stations 12 and 13 (nodes in the hepatoduodenal ligament and retropancreatic nodes). Finally the gastric lymphatics drain into nodal station 16 by using 4 different pathways, named lymphatic pedicles. Essentially, pedicles are connections between the lymph pathways and namely are a) the left subdiaphragmatic and the celiac pedicles, mainly responsible for the upper and middle portion of the stomach and b) the superior mesenteric and the retropancreatic pedicles, mainly responsible for the middle and lower portion of the stomach, each forming from the connection of lymphatics.

Concerning the lymphatic flow with respect to the curvatures of the stomach a) nodes of the greater curvature of the stomach, mainly drain towards the infra-pyloric nodes and finally the superior mesenteric pedicle, but also towards the splenic artery and hilum nodes and then directly to station 16 and b) nodes of the lesser curvature drain towards nodes along the celiac trunk and the left gastric artery, along with those located right of the cardia stomach [10–14].

LYMPHATIC SPREAD IN GASTRIC CARCINOMAS

Gastric carcinomas (GC) is the fifth most common cancer and the third most lethal cancer worldwide [69, 70]. Men are afflicted twice more frequently than women and regarding the geographical distribution high risk regions include East Asia and Europe and South America, as well as developing countries, which account for 50% of the cases [68–70].

GC are classified according to morphological classifications that include the World Health Organization (WHO) classification (papillary, tubular, mucinous, signet ring, and poorly cohesive) and the Lauren classification (intestinal, diffuse, and mixed) [62, 68–70]. However, there is growing evidence showing multiple genetic and epigenetic alterations resulting in the dysregulation of various oncogenes and tumor suppressor genes which is considered to be the driver during the GC oncogenesis [44, 45]. Therefore, various molecular classifications of GC have been developed which may have impact on determining prognosis an/or predicting treatment responsiveness [44, 45].

The prognosis of GS correlates with the stage of the carcinoma determined at diagnosis according to the depth of tumor invasion (T), lymph node involvement (N) and metastasis (M) [63]. GC is usually classified into two subgroups: early GC and advanced GC [9, 62]. Early GC affects the mucosa or the mucosa and submucosa (T1), irrespective of tumor size and lymph node (LN) involvement and has 5-year survival rate > 90% whereas advanced GC affects deeper layers (T2-T4) and has a 5-year survival rate of 7–27% [9, 62, 68–70].

The basis for the treatment of the GC is the enlistment of a multidisciplinary team with a variety of medical disciplines such as surgery, radiation and medical oncology, and gastroenterology. Based on the guidelines of NCCN, published in 2022 new patients should have a complete workup starting from physical examination and ending with specialized imaging exams such as CT-scans, FDG-PET/CT scans and Endoscopic Ultrasonography, with the last being especially useful in early disease [67]. The type of treatment to be implemented is largely determined by the stage of the tumor, with early stage or localized disease (cTis-cT1a) possibly being treated only with endoscopic treatment, locoregional disease (cT1b-cT4a, cM0) with excisional surgery if achievable and metastatic cancer (cT4b, cM1) with systemic palliative treatment, comprised of various pharmaceutical schemes and symptom alleviating surgery [67]. The recurrence rates after gastric surgery remain high (ranging from 20% to 50%) and LN involvement has the strongest influence on recurrence and prognosis of GC [17, 18, 62, 67–70].

The surgical treatment comprises gastrectomy and lymphadenectomy

Four main types of gastrectomy can be performed based on the location of the tumor as summarized by Maru P. et al., 2021 [66]. The types are a) Total gastrectomy, for diffuse carcinomas, large distal tumors, and the carcinomas involving body or lesser curvature of stomach, b) Esophago-gastrectomy for carcinomas involving cardia and gastroesophageal junction c) Distal subtotal gastrectomy for carcinomas limited to distal stomach and d) Proximal gastrectomy with excision of lower mediastinal LN for gastroesophageal junction tumor infiltrating less than 3 cm into the lower esophagus [66].

The types of lymphadenectomy is a subject of debate since the decision concerning the approach of LN dissection is crucial for the staging and the prognosis of the disease. [37–54]. The types of lymphadenectomy are the following: D1 lymphadenectomy, which is the removal of perigastric nodes, including stations 1–7 in a total gastrectomy, D1+ lymphadenectomy, which is a D1 excision along with stations 8a, 9, 11p, D2 lymphadenectomy, which adds stations 8a, 9, 10, 11p, 11d and 12a to D1 dissection and D3 lymphadenectomy, which is more extensive than D2, including also nodal stations 13–16 [50–54, 66, 69].

The question that arises is which of these types of lymphadenectomy is to be implemented. [Degiuli M.](#), et al., 2016, reported that nowadays ,also in western countries, D2 surgical procedure can be carried out without spleno-pancreatectomy and several national guidelines suggest D2 gastrectomy as the recommended procedure for patients with advanced GC [14]. [Coburn N.](#), et al., 2018, in a systematic review showed the increased peri-operative danger of D2 lymphadenectomy but also the decrease in disease recurrence compared to D1 lymphadenectomy [53]. [Douridas G.](#) et al., 2018, reported no benefit of D3 lymphadenectomy regarding the overall survival, and, in addition, the advanced difficulty of this operation, the extended operation time and increased probability for reoperation, render D3 lymphadenectomy probably inferior than D2 lymphadenectomy, at least in a routine base [54]. [Rosa F.](#) et al., 2022, reported that the resection of at least 16 LN is required for proper staging and that D2 might also be beneficial as it includes a great number of excised LN on average [52]. Other studies have reported that the number of LN harvested after D2 distal gastrectomy can exceed 40 [40–42]. It has been reported that a greater number of harvested LN is associated with better prognosis [39, 62]. On the other hand, early GC, presenting a metastatic pattern that concerns perigastric LN and stations 7, 8a and 9 has no benefit from D2 lymphadenectomy and D1+ lymphadenectomy is sufficient [53]. From these studies, but also from the NCCN guidelines, D2 lymphadenectomy, seems to have a place in the cure of

advanced disease, due to the more radical disease excision and higher survival rates, and is a tool to be used by experienced surgeons [51, 53, 54, 67]. Notably, Aiolfi A. et al. [30] used meta-analysis to evaluate 5 randomized controlled trials (RCTs) to compare the effect of D2 vs. D1 on survival in 1653 patients, of which 805 patients (48.7%) underwent D2 lymphadenectomy. The Restricted mean survival time difference (RMSTD) overall survival (OS) analysis showed that at 60-month follow-up, patients with D2 lymphadenectomy lived 1.8 months ($P = 0.14$) longer on average compared to D1 patients [30]. Similarly, 60-month disease-free survival (DFS) (0.8 months, $P = 0.53$) and cancer-specific survival (CSS) (1.2 months, $P = 0.72$) tended to be improved for D2 vs. D1 lymphadenectomy [30]. Aiolfi A. et al. [30] concluded that, in comparison to D1, D2 lymphadenectomy is associated with a trend toward improved OS, CSS, and DFS at 60-month follow-up.

LN metastasis is a common form of metastasis in patients with GC [47, 53, 65]. The relatively high rate of LN metastasis in patients with GC can be, at least in part, attributed to the rich lymphatic network in the stomach which can be evidenced by immunohistochemistry [61]. Indeed, Yonemura Y. et al. [61] analyzed by immunohistological staining using the D2-40 antibody the topographical distribution of the lymphatic vessels in the normal human stomach. They observed a) lymphatic vessels in the lamina propria of the fundic gland, parietal cell area and pyloric gland areas, b) abundant lymphatic vessels in the superficial layer of the muscularis mucosa and the upper half layer of the submucosa, c) scarce lymphatic vessels in the lower half layer of the submucosa and d) many lymphatic vessels in the inner and outer layers of the proper muscle [61]. The rich lymphatic vessel network in muscularis mucosa and submucosa of the stomach could provide an explanation why LN metastasis occur even in early GC [61].

The overall prevalence of LN metastases in T1 GC is 8–31%, while the overall prevalence of LN metastases in T2-T4 GC is considerably higher; 45–90% [43, 48]. Concerning early GC (EGC), a meta-analysis showed LN metastasis in about 3.2% (0.0–20.3%) of mucosal EGC and 19.2% (10.2–33.3%) of submucosal EGC [41].

Concerning the prevalence of LN metastases in the individual LN stations for different T-stages the results of a meta-analysis were the following [43]. Concerning the LN stations 1 to 7, the LN along the lesser gastric curvature (station 3) show the highest metastatic rate (T1: 5.5%, T2: 21.9%, T3: 41.9%, T4: 71.0%). Concerning the LN stations 8 to 20, the LN around the common hepatic artery (station 8) show the highest metastatic rate (T1: 0.8%, T2: 7.9%, T3: 14.0%, T4: 28.2%) [43].

Concerning the frequency of LN metastasis according to the anatomic location of the tumor, GC of the upper third of the stomach present more frequently LN metastasis ranging from 44% up to 80% of cases, whereas the respective frequencies of the middle and the lower parts range from 37–65% to 50–59% [11, 12, 16, 40, 42].

Concerning the anatomical location of the metastatic LN in relation to the anatomic location of the tumor, a) malignancies of the upper third of the stomach more frequently infiltrate nodes in the lesser curvature and paracardial nodes, b) tumors of the middle third more frequently invade the nodes in both the lesser and greater curvature and in the right paracardial station and c) tumors of the lower third more frequently infiltrate the infrapyloric nodes and those situated along the lesser and greater curvature, with a preference for nodes along the right gastroepiploic artery [11, 12]. From the three parts of the stomach, tumors of the upper third are the most probable to present nodal spread towards paraortic nodes and nodes of the splenic hilum, and tumors from all the parts of the stomach give metastasis to nodes around the celiac trunk [11, 12].

The prognostic significance of LN metastasis in GC was related to the number of positive LN, the LN density which is also called LN ratio (ratio of positive to total examined LN) and the number of negative LN [14, 27–29, 59, 60, 69, 70]. Indeed, the increased number of positive LN is associated with higher possibility of recurrence and lower survival [14, 60, 69, 70]. Moreover, a meta-analysis of 27 studies (a total of 11,441 patients) showed that higher LN ratios were significantly associated with a shorter OS and LN ratio was an independent predictor of survival [29]. Furthermore, the increased numbers of negative LN are associated with better prognosis [55–57, 65]. For example, Bahardoust M. et al., 2023, studied 639 patients who were divided, based on the number of negative LN, into three subgroups, including (0–9 negative LN), (10–15 negative LN), and (≥ 16 negative LN), removed, including 155, 231, and 253 GC patients, respectively [56]. Their results revealed that the number of negative LN resected ≥ 16 was associated with an increased 5-year survival rate and a decreased recurrence rate in GC patients after gastrectomy [56]. Similarly, Wang X et al. studied 7660 GC patients and provided evidence for the superiority of the ratio of negative to positive LN dissected compared to already used systems, such as the TNM staging system and the ratio of positive to total LN, which did not take into account the number of negative LN [55]. The prognostic significance of the negative LN could be explained by the fact that a larger number of LN is indicative of a higher quality of surgery and by indications that negative LN play a protective and immune-enhancing role in defense potential against the tumor [56–58]. Interestingly, Li Y. et al. [24] assessed the prognostic value of log odds of

positive LN (LODDS) compared to pathological classification and ratio-based LN system (pN and rN respectively). This study managed to deem LODDS as a more accurate predictor of the survival of GC patients compared to already established methods. One of the factors that mostly affects the prognostic value of LODDS is that of neo-adjuvant therapy, with patients that received therapy presenting with better OS compared to patients that did not, despite being on the same LODDS group [24].

In addition to the prognostic value of the number of metastatic LN which determine the nodal stage in the GC TNM staging system [63], the incorporation of the anatomical location of the metastatic LN may also have prognostic impact [33–35]. In this regard, Jeon C. H. et al. [35] analyzed 3591 patients with LN metastases who were classified into the perigastric (stations 1–6, group P) or extragastric (stations 7–12) groups. The extragastric group was further subdivided into the near-extragastric (stations 7–9, group NE) and far-extragastric (stations 10–12, group FE) groups. No statistically significant survival differences were found between group P and the extragastric group in each N stage. However, in N1 and N2, group FE showed statistically significant worse survival than the other groups ($P = 0.013$ for N1, $P < 0.001$ for N2), but not in N3. In the subgroup analysis, group FE had a statistically significant lower OS in N2, regardless of the cancer location. Jeon C. H. et al. [35] concluded that, although this big data analysis confirmed the superiority of the current numerical nodal staging system, in N1 and N2 in which there is an upper limit on metastatic LN, attention should be paid to the potential significance of the anatomical information for specific nodal stations [35]. Moreover, Jeong O. et al. analyzed 3350 patients and they found that the anatomic region of the metastatic LN (perigastric vs extra-perigastric) improved the goodness-of-fit of the prognostic model using the TNM stage [34]. They concluded that the anatomic region of metastatic LN has an independent prognostic value in the numeric N stage in the current TNM staging system [34]. Furthermore, Zhao B. et al., 2018, reviewed 1451 GC patients who underwent radical gastrectomy and found that the anatomical location of metastatic LN is an indispensable prognostic factor [33].

The search for predictors of LN metastasis in GC is an important issue and was recently reviewed in studies using meta-analysis. For example, [Li Y.](#) et al. [26] analyzed 41 studies (56182 patients) and showed that machine learning (ML) is of excellent diagnostic performance in predicting the LN metastasis in GC patients and, more specifically, models which are based on radiomics and clinical features showed better accuracy than those including only clinical predictors. The most commonly used predictors were tumor size, depth of tumor invasion, histologic differentiation, imaging techniques, lymphovascular invasion,

tumor location, CT reported LN, age and macroscopic features [26]. Moreover, Jiang B. et al. [25] sought predictors of LN metastasis and residual tumor in early GC patients after noncurative endoscopic resection. They analyzed, 12 studies (3015 patients), 7 of which also involved carcinoma residues. Six predictors, including a) size of the tumor > 30 mm, b) invasion depth of the carcinoma (> 500 μ m from the muscularis mucosae), c) macroscopic appearance of the tumor, d) undifferentiated histological type of the carcinoma, e) positive vertical tumor margin, and f) presence of lymphovascular invasion (including lymphatic invasion and blood vessel invasion) were significantly associated with LN metastasis [25]. In addition, tumor size > 30 mm, positive horizontal tumor margin, and positive vertical tumor margin were identified as significant predictors for the risk of residual tumor [25]. Furthermore, Abdelfatah M. M. et al., 2018, reviewed the LN metastatic risk in early GC according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association [15]. The review of 12 studies (total 9798 patients) showed that a) differentiated mucosal lesions regardless of size and ulcerated lesions = < 3 cm could be endoscopically resected without additional risk of LN metastasis and b) early GC presenting even < 500 μ m of submucosal invasion have a much greater LN metastasis risk that should be weighed against the relative risk of a surgery including gastrectomy and lymphadenectomy [15].

There is evidence that the patterns of anatomical distribution of LN metastasis are related to the anatomical location of the primary tumor. Indeed, Brisinda G. et al., 2023, analyzed 1,510 patients including advanced and early GC patients who underwent a gastrectomy documented that in 162 N+ patients with distal GC (Middle and Lower thirds) the distribution of LN metastases at individual nodal stations is closely related to primary carcinoma location [38]. Moreover, Han K. B. et al., 2011, analyzed 1,510 patients including early GC patients and found that the pattern of LN metastasis depends on the location of GC [37]. For example, in all patients, LN station numbers 1, 2, 3, 7, 10 and 11 metastases were dominant in the GC originating in the upper third, whereas LN station numbers 4, 5, 6 and 8 metastases were dominant in the GC originating in the lower third [37]. On the other hand, de Jongh C. et al., 2022, analyzed 212 patients and observed that although proximal tumors metastasized predominantly to proximal LN stations (no. 1, 2, 7 and 9; $P < 0.05$) and distal tumors to distal LN stations (no. 5, 6 and 8; $P > 0.05$), in addition, distal tumors also metastasized to proximal LN stations, and *vice versa* [36]. They concluded that although the pattern of LN metastases is related to tumor location, all LN stations contained metastatic disease regardless of GC

location, cT-stage (including cT1N0-tumors), histological type, or neoadjuvant chemotherapy (NAC) treatment [36].

Mention should be made to the study of Kinami S. et al., 2021, who proposed a new classification system, the nPTD (new proximal — transitional — distal) classification which results from the correlation between GC anatomical location and physiological lymphatic flow distribution using the dye method of sentinel node biopsy [31]. Kinami S. et al., retrospectively studied 416 GC patients using as inclusion criteria the following: a single lesion type 0 cancer of ≤ 5 cm in the long axis, clinically node-negative, and pathological invasion within the proper muscle layer [31]. The study of Kinami S. et al. is based on the concept of the lymphatic basin which is a certain lymphatic area that drains directly from the primary GC focus. The lymphatic basins were defined as follows: the proximal side was the stomach wall, and the distal side was the most distal dye-stained LN [31]. The main results of this study were the following: a) the carcinomas located in the watershed of the left and right gastroepiploic arteries near the greater curvature of the stomach had extensive lymphatic flow; therefore, a newly circular region with a diameter of 5 cm was set on the watershed of the greater curvature between proximal and transitional zone as the 'n' zone, and b) for carcinomas located in the lesser proximal curvature, lymphatic flow to the greater curvature of the stomach was not found; therefore, the proximal zone was divided into two zones: the lesser curvature side and the greater curvature side [31]. Kinami S. et al. concluded that the advantage of the nPTD classification is that it provides proper LN dissection and adequate function-preserving gastrectomy [31].

A novel pathologist/surgeon team approach in order to harvest the maximum number of LN, following radical gastrectomy was very recently reported by Ambrosio M. R. et al. [51]. Indeed, both the surgeon and pathologist were present in the operative room and implicated in an on-site macroscopic examination and dissection of a fresh tissue specimen. This protocol identified more LN even in GC patients receiving neoadjuvant therapy. Based on these preliminary results, the pathologist/surgeon team approach allows for the harvesting of a larger number of LN and improves the outcome of the patients thanks to more precise staging and therapy [51]. Nevertheless, a higher number of patients are necessary to confirm these findings and assess the impact of this technique on oncological outcome,

Although the aforementioned information is essential to understand the nodal metastatic patterns of the GC, mention should be made to the concept of skip metastasis [11, 12]. Skip metastasis is the presence of a metastatic LN in an extraperigastric area without involvement of perigastric LN [22, 23]. The skip metastasis pattern and the complicated lymphatic

drainage may limit the application of sentinel LN biopsy in GC patients [11, 12, 19–23]. The incidence of skip metastasis ranges from 5–14% concerning mainly LN along the common hepatic artery, the left gastric artery, and the celiac trunk, but this percentage presents variations [11, 12, 21–23]. Choi Y. Y. et al. [23] analyzed 2,231 patients and reported that 2,231 (37.0 %) had metastatic LN. Specifically, 1,137/2,231 patients (51.0%) had metastatic LN around the stomach only (Perigastric area), and 988/2,231 patients (44.3%) had metastatic LN in both the Perigastric area and the Extraperigastric area. The incidence of skip metastasis was 4.8% (106/2,231 patients) among the patients having metastatic LN, and 1.8% among the overall GC population [23]. In terms of topography, the commonest location of skip metastasis was nodal station 7 around the left gastric artery (67/106 patients, 63.2 %), followed by nodal station 8 (around the common hepatic artery) and nodal station 9 (around the celiac axis) (33.0 and 30.2%, respectively [23]. The skip metastasis was found in only one nodal station in 83/106 patients (79.2%) [23]. In another study including 1,343 GC patients, the incidence of skip metastasis was 3.9% in all examined GC patients, the most common anatomical location of skip metastasis was No.7 and No.8a node station and the proportion of only one involved node station accounted for 83.0% of all GC cases [22]. The prognosis of the skip group was worse than that of the Perigastric-only group and similar to that of the Perigastric + Extraperigastric group when the tumor stage was considered [22, 23]. Possible explanations for the occurrence of skip metastasis may be aberrant and complicated lymphatic network, occult metastases and inadequate LN sampling [11, 12, 21–23]. It is noteworthy that several studies found that the skip metastasis group had fewer number of retrieved LN than the Perigastric-only and Perigastric + Extraperigastric groups, especially in the perigastric area [20–23]. Therefore, the impact of inadequate number of retrieved LN on the identification of skip metastasis should be carefully considered.

Finally it is important to summarize the tools available for the pre-, intra- and post-operative specific diagnosis of LN metastasis. CT scans, FDG-PET/CT and Endoscopic Ultrasonography are the main tools used to help the surgeon to locate enlarged LN in the perigastric area or in further stations (para-aortic, celiac, mediastinal etc.). The future tools may be methods to predict the LN metastasis based on the characteristics of the initial lesion including location and molecular markers [47]. Intraoperative biopsy could be implemented in specific cases, such as localized cancer or patients with tumors smaller than 5cm , but it does not seem to provide additional benefit compared to CT scans regarding the identification of LN spread [46, 47]. Postoperatively, the classification of LN metastasis based on location and number of LN has already been discussed [32–35]. In order to harvest a large number of LN

there are important LN sorting technologies including a) the Fine LN Sorting, which provides a larger number of LN per specimen and b) the Regional LN Sorting which is time-saving and examines more LN but is not so widely applied [54].

CONCLUSIONS

Lymphatic vasculature plays a vital role in physiology and is involved in many pathological conditions such as lymphedema and tumor metastasis. The knowledge of the lymphatic drainage pathways from each organ is important for the understanding and the prediction of the site of occurrence of LN metastasis. GC remains the fifth most common cancer and the third most common cause of cancer mortality. Most patients diagnosed with GC gastric cancer still have a poor prognosis due to its advanced presentation at diagnosis, even in countries with developed screening programs. Surgery is the cornerstone of the treatment for GC, often combined with perioperative chemotherapy. LN dissection is an important component of the surgical treatment of GC. D1 lymphadenectomy is currently recommended for early stage tumors. However, the extent of lymphadenectomy in advanced GC gastric cancer, is still a matter of debate between Western and Eastern approaches. Although a D2 dissection is the current standard recommended by most guidelines, there might be a place for more limited dissections such as D1 + in selected cases. This article aimed to present a comprehensive review of the gastric lymphatic anatomy and its importance in the pathology, treatment and prognosis of gastric carcinomas.

ARTICLE INFORMATION AND DECLARATIONS

Author contributions

Dimosthenis Chrysikos and Panagiotis Kanavaros came up with the concept and design of the article. Panagiotis Kanavaros, Dimosthenis Chrysikos, Ameer Shehade, Alexandros Samolis and Dimitrios Liatsos were in charge of acquiring, analyzing and interpreting the data. Dimosthenis Chrysikos, Panagiotis Kanavaro and Dimitrios Liatsos drafted the initial versions of the paper. Alexandra Barbouti and Theodore Troupis revised the article critically for important intellectual content.

Lastly, all authors equally approved the final version of the manuscript that we are submitting

Funding

This article was not supported by sponsors and no funds were received.

Acknowledgments

No further acknowledgements are to be made.

Conflict of interest

The authors state that there is no conflict of interest.

REFERENCES

1. Singhal D, Börner K, Chaikof EL, et al. Mapping the lymphatic system across body scales and expertise domains: A report from the 2021 National Heart, Lung, and Blood Institute workshop at the Boston Lymphatic Symposium. *Front Physiol.* 2023;14:1099403. doi:10.3389/fphys.2023.1099403.
2. Mehrara BJ, Radtke AJ, Randolph GJ, et al. The emerging importance of lymphatics in health and disease: an NIH workshop report. *J Clin Invest.* 2023;133(17). doi:10.1172/jci171582.
3. Oliver G, Kipnis J, Randolph GJ, et al. The Lymphatic Vasculature in the 21(st) Century: Novel Functional Roles in Homeostasis and Disease. *Cell.* 2020;182(2):270-96. doi:10.1016/j.cell.2020.06.039.
4. Skandalakis JE, Skandalakis LJ, Skandalakis PN. Anatomy of the lymphatics. *Surg Oncol Clin N Am.* 2007;16(1):1-16. doi:10.1016/j.soc.2006.10.006.
5. Hsu MC, Itkin M. Lymphatic Anatomy. *Tech Vasc Interv Radiol.* 2016;19(4):247-54. doi:10.1053/j.tvir.2016.10.003.
6. Ulvmar MH, Mäkinen T. Heterogeneity in the lymphatic vascular system and its origin. *Cardiovasc Res.* 2016;111(4):310-21. doi:10.1093/cvr/cvw175.
7. Petrova TV, Koh GY. Biological functions of lymphatic vessels. *Science.* 2020;369(6500). doi:10.1126/science.aax4063.
8. Adamczyk LA, Gordon K, Kholová I, et al. Lymph vessels: the forgotten second circulation in health and disease. *Virchows Arch.* 2016;469(1):3-17. doi:10.1007/s00428-016-1945-6.
9. Young JJ, Pahwa A, Patel M, et al. Ligaments and Lymphatic Pathways in Gastric Adenocarcinoma. *Radiographics.* 2019;39(3):668-89. doi:10.1148/rg.2019180113.
10. Cho HS, Ahn JH. Nomenclature and Lymphatic Drainage Patterns of Abdominal Lymph Nodes. *J Korean Soc Radiol.* 2022;83(6):1240-58. doi:10.3348/jksr.2021.0189.

11. de Manzoni G, Roviello F, Di Leo A, et al. Lymphatic Spread, Lymph Node Stations, and Levels of Lymphatic Dissection in Gastric Cancer. In: de Manzoni G, Roviello F, Siquini W, editors. *Surgery in the Multimodal Management of Gastric Cancer*. Milano: Springer Milan; 2012. p. 15-23.
12. Lirosi MC, Biondi A, Ricci R. Surgical anatomy of gastric lymphatic drainage. *Transl Gastroenterol Hepatol*. 2017;2:14. doi:10.21037/tgh.2016.12.06.
13. Rosa F, Costamagna G, Doglietto GB, et al. Classification of nodal stations in gastric cancer. *Transl Gastroenterol Hepatol*. 2017;2:2. doi:10.21037/tgh.2016.12.03.
14. Degiuli M, De Manzoni G, Di Leo A, et al. Gastric cancer: Current status of lymph node dissection. *World J Gastroenterol*. 2016;22(10):2875-93. doi:10.3748/wjg.v22.i10.2875.
15. Abdelfatah MM, Barakat M, Lee H, et al. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis. *Gastrointest Endosc*. 2018;87(2):338-47. doi:10.1016/j.gie.2017.09.025.
16. Ishikawa S, Shimada S, Miyanari N, et al. Pattern of lymph node involvement in proximal gastric cancer. *World J Surg*. 2009;33(8):1687-92. doi:10.1007/s00268-009-0083-6.
17. Barchi LC, Yagi OK, Jacob CE, et al. Predicting recurrence after curative resection for gastric cancer: External validation of the Italian Research Group for Gastric Cancer (GIRCG) prognostic scoring system. *Eur J Surg Oncol*. 2016;42(1):123-31. doi:10.1016/j.ejso.2015.08.164.
18. Marrelli D, De Stefano A, de Manzoni G, et al. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. *Ann Surg*. 2005;241(2):247-55. doi:10.1097/01.sla.0000152019.14741.97.
19. Lee JH, Lee HJ, Kong SH, et al. Analysis of the lymphatic stream to predict sentinel nodes in gastric cancer patients. *Ann Surg Oncol*. 2014;21(4):1090-8. doi:10.1245/s10434-013-3392-9.
20. Park SS, Ryu JS, Min BW, et al. Impact of skip metastasis in gastric cancer. *ANZ J Surg*. 2005;75(8):645-9. doi:10.1111/j.1445-2197.2005.03485.x.
21. Kim DH, Choi MG, Noh JH, et al. Clinical significance of skip lymph node metastasis in gastric cancer patients. *Eur J Surg Oncol*. 2015;41(3):339-45. doi:10.1016/j.ejso.2014.09.009.
22. Zhao B, Mei D, Zhang J, et al. Impact of skip lymph node metastasis on the prognosis of gastric cancer patients who underwent curative gastrectomy. *J buon*. 2019;24(2):693-700.

23. Choi YY, An JY, Guner A, et al. Skip lymph node metastasis in gastric cancer: is it skipping or skipped? *Gastric Cancer*. 2016;19(1):206-15. doi:10.1007/s10120-015-0472-5.
24. Li Y, Wu G, Liu J, et al. Log odds of positive lymph nodes as a novel prognostic predictor for gastric cancer: a systematic review and meta-analysis. *BMC Cancer*. 2023;23(1):523. doi:10.1186/s12885-023-10805-6.
25. Jiang B, Zhou L, Lu J, et al. Predictors of lymph node metastasis and residual tumor in early gastric cancer patients after noncurative endoscopic resection: a systematic review and meta-analysis. *Therap Adv Gastroenterol*. 2020;13:1756284820935033. doi:10.1177/1756284820935033.
26. Li Y, Xie F, Xiong Q, et al. Machine learning for lymph node metastasis prediction of in patients with gastric cancer: A systematic review and meta-analysis. *Front Oncol*. 2022;12:946038. doi:10.3389/fonc.2022.946038.
27. Kano K, Yamada T, Yamamoto K, et al. Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer. *Ann Surg Oncol*. 2020;27(11):4235-47. doi:10.1245/s10434-020-08616-1.
28. Jiang J, Chen J, Zhang H, et al. Combination of the ratio between metastatic and harvested lymph nodes and negative lymph node count as a prognostic indicator in advanced gastric cancer: a retrospective cohort study. *J Gastrointest Oncol*. 2021;12(5):2022-34. doi:10.21037/jgo-21-212.
29. Zhu J, Xue Z, Zhang S, et al. Integrated analysis of the prognostic role of the lymph node ratio in node-positive gastric cancer: A meta-analysis. *Int J Surg*. 2018;57:76-83. doi:10.1016/j.ijssu.2018.08.002.
30. Aiolfi A, Bona D, Bonitta G, et al. Long-Term Impact of D2 Lymphadenectomy during Gastrectomy for Cancer: Individual Patient Data Meta-Analysis and Restricted Mean Survival Time Estimation. *Cancers (Basel)*. 2024;16(2). doi:10.3390/cancers16020424.
31. Kinami S, Nakamura N, Miyashita T, et al. nPTD classification: an updated classification of gastric cancer location for function preserving gastrectomy based on physiological lymphatic flow. *BMC Cancer*. 2021;21(1):1231. doi:10.1186/s12885-021-08936-9.
32. Choi YY, An JY, Katai H, et al. A Lymph Node Staging System for Gastric Cancer: A Hybrid Type Based on Topographic and Numeric Systems. *PLoS One*. 2016;11(3):e0149555. doi:10.1371/journal.pone.0149555.

33. Zhao B, Zhang J, Zhang J, et al. Anatomical location of metastatic lymph nodes: an indispensable prognostic factor for gastric cancer patients who underwent curative resection. *Scand J Gastroenterol.* 2018;53(2):185-92. doi:10.1080/00365521.2017.1415371.
34. Jeong O, Jung MR, Kang JH. Prognostic Value of the Anatomic Region of Metastatic Lymph Nodes in the Current TNM Staging of Gastric Cancer. *J Gastric Cancer.* 2021;21(3):236-45. doi:10.5230/jgc.2021.21.e22.
35. Jeon CH, Park KB, Lee H, et al. Refining gastric cancer staging: examining the interplay between number and anatomical location of metastatic lymph nodes - a retrospective multi-institutional study. *BMC Cancer.* 2023;23(1):1192. doi:10.1186/s12885-023-11653-0.
36. de Jongh C, Triemstra L, van der Veen A, et al. Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial. *Gastric Cancer.* 2022;25(6):1060-72. doi:10.1007/s10120-022-01329-2.
37. Han KB, Jang YJ, Kim JH, et al. Clinical significance of the pattern of lymph node metastasis depending on the location of gastric cancer. *J Gastric Cancer.* 2011;11(2):86-93. doi:10.5230/jgc.2011.11.2.86.
38. Brisinda G, Chiarello MM, Fico V, et al. Pattern of Distribution of Lymph Node Metastases in Individual Stations in Middle and Lower Gastric Carcinoma. *Cancers (Basel).* 2023;15(7). doi:10.3390/cancers15072139.
39. Macalindong SS, Kim KH, Nam BH, et al. Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. *BMC Cancer.* 2018;18(1):73. doi:10.1186/s12885-017-3872-6.
40. Shen KH, Wu CW, Lo SS, et al. Factors correlated with number of metastatic lymph nodes in gastric cancer. *Am J Gastroenterol.* 1999;94(1):104-8. doi:10.1111/j.1572-0241.1999.00779.x.
41. Kwee RM, Kwee TC. Predicting lymph node status in early gastric cancer. *Gastric Cancer.* 2008;11(3):134-48. doi:10.1007/s10120-008-0476-5.
42. Di Leo A, Marrelli D, Roviello F, et al. Lymph node involvement in gastric cancer for different tumor sites and T stage: Italian Research Group for Gastric Cancer (IRGGC) experience. *J Gastrointest Surg.* 2007;11(9):1146-53. doi:10.1007/s11605-006-0062-2.
43. de Jong MHS, Gisbertz SS, van Berge Henegouwen MI, et al. Prevalence of nodal metastases in the individual lymph node stations for different T-stages in gastric cancer: a systematic review. *Updates Surg.* 2023;75(2):281-90. doi:10.1007/s13304-022-01347-w.

44. Wang Q, Liu G, Hu C. Molecular Classification of Gastric Adenocarcinoma. *Gastroenterology Res.* 2019;12(6):275-82. doi:10.14740/gr1187.
45. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature.* 2014;513(7517):202-9. doi:10.1038/nature13480.
46. Kinami S, Nakamura N, Tomita Y, et al. Precision surgical approach with lymph-node dissection in early gastric cancer. *World J Gastroenterol.* 2019;25(14):1640-52. doi:10.3748/wjg.v25.i14.1640.
47. Kinami S, Saito H, Takamura H. Significance of Lymph Node Metastasis in the Treatment of Gastric Cancer and Current Challenges in Determining the Extent of Metastasis. *Front Oncol.* 2021;11:806162. doi:10.3389/fonc.2021.806162.
48. Liu X, Long Z, Cai H, et al. Analysis of lymph node metastasis correlation with prognosis in patients with T2 gastric cancer. *PLoS One.* 2014;9(8):e105112. doi:10.1371/journal.pone.0105112.
49. Kurokawa Y, Doki Y, Mizusawa J, et al. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001). *Br J Surg.* 2022;110(1):50-6. doi:10.1093/bjs/znac373.
50. Marano L, Carbone L, Poto GE, et al. Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues. *Curr Oncol.* 2023;30(1):875-96. doi:10.3390/curroncol30010067.
51. Ambrosio MR, Perotti B, Battini A, et al. Surgeon-Pathologist Team Approach Dramatically Affects Lymph Nodes Detection and Improves Patients' Short-Term Outcome. *Cancers (Basel).* 2022;14(4). doi:10.3390/cancers14041034.
52. Rosa F, Schena CA, Laterza V, et al. The Role of Surgery in the Management of Gastric Cancer: State of the Art. *Cancers (Basel).* 2022;14(22). doi:10.3390/cancers14225542.
53. Coburn N, Cosby R, Klein L, et al. Staging and surgical approaches in gastric cancer: A systematic review. *Cancer Treat Rev.* 2018;63:104-15. doi:10.1016/j.ctrv.2017.12.006.
54. Douridas GN, Pierrakakis SK. Is There Any Role for D3 Lymphadenectomy in Gastric Cancer? *Front Surg.* 2018;5:27. doi:10.3389/fsurg.2018.00027.
55. Wang X, Wang P, Wang W, et al. Evaluation of the prognostic value of negative to positive lymph node ratio in gastric cancer: results from multi-institutional cohorts from western and eastern datasets - Cohort study. *Ann Med Surg (Lond).* 2023;85(6):2348-55. doi:10.1097/ms9.0000000000000775.
56. Bahardoust M, Kheirabadi M, Donyadideh G, et al. Effect of the number of negative lymph nodes removed on the survival and recurrence rate after gastrectomy in patients with

gastric cancer: a multicenter retrospective cohort study. *BMC Surg.* 2023;23(1):246. doi:10.1186/s12893-023-02154-9.

57. da Costa PM, Lages P, Onofre S, et al. The impact of negative lymph nodes in the survival outcomes of pN+ patients following radical gastrectomy: the inverse lymph node ratio as a better score to study negative lymph nodes. *Updates Surg.* 2020;72(4):1031-40. doi:10.1007/s13304-020-00757-y.

58. Huang CM, Lin JX, Zheng CH, et al. Effect of negative lymph node count on survival for gastric cancer after curative distal gastrectomy. *Eur J Surg Oncol.* 2011;37(6):481-7. doi:10.1016/j.ejso.2011.01.012.

59. Liu Y, Cui H, Xu X, et al. Prognostic value of lymph node density on cancer staging system for gastric cancer without distal metastasis: a population-based analysis of SEER database. *World J Surg Oncol.* 2022;20(1):325. doi:10.1186/s12957-022-02795-9.

60. Deng J, Liang H, Sun D, et al. The prognostic analysis of lymph node-positive gastric cancer patients following curative resection. *J Surg Res.* 2010;161(1):47-53. doi:10.1016/j.jss.2008.12.019.

61. Yonemura Y, Endou Y, Tabachi K, et al. Evaluation of lymphatic invasion in primary gastric cancer by a new monoclonal antibody, D2-40. *Hum Pathol.* 2006;37(9):1193-9. doi:10.1016/j.humpath.2006.04.014.

62. López Sala P, Leturia Etxeberria M, Inchausti Iguñiz E, et al. Gastric adenocarcinoma: A review of the TNM classification system and ways of spreading. *Radiologia (Engl Ed).* 2023;65(1):66-80. doi:10.1016/j.rxeng.2022.10.011.

63. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J Clin.* 2017;67(2):93-9. doi:10.3322/caac.21388.

64. Japanese classification of gastric carcinoma: 3rd English edition. *Gastric Cancer.* 2011;14(2):101-12. doi:10.1007/s10120-011-0041-5.

65. Deng JY, Liang H. Clinical significance of lymph node metastasis in gastric cancer. *World J Gastroenterol.* 2014;20(14):3967-75. doi:10.3748/wjg.v20.i14.3967.

66. Maru P, Roy B, Sen S, et al. Imaging of Gastric Carcinoma. Part Two: Lymph node mapping in Gastric Carcinoma. *Journal of Gastrointestinal and Abdominal Radiology.* 2021;4(03):206-13. doi:10.1055/s-0040-1722795.

67. Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2022;20(2):167-92. doi:10.6004/jnccn.2022.0008.

68. López MJ, Carbajal J, Alfaro AL, et al. Characteristics of gastric cancer around the world. *Crit Rev Oncol Hematol*. 2023;181:103841. doi:10.1016/j.critrevonc.2022.103841.
69. Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. *Lancet*. 2020;396(10251):635-48. doi:10.1016/s0140-6736(20)31288-5.
70. Machlowska J, Baj J, Sitarz M, et al. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. *Int J Mol Sci*. 2020;21(11). doi:10.3390/ijms21114012.